Abstract
The global burden of type 2 diabetes is increasing worldwide, and successful treatment of this disease needs constant provision of new drugs. Twelve classes of antidiabetic drugs are currently available, and many new drugs are under clinical development. These include compounds with known mechanisms of action but unique properties, such as once-weekly DPP4 inhibitors or oral insulin. They also include drugs with new mechanisms of action, the focus of this review. Most of these compounds are in Phase 1 and 2, with only a small number having made it to Phase 3 at this time. The new drug classes described include PPAR agonists/modulators, glucokinase activators, glucagon receptor antagonists, anti-inflammatory compounds, G-protein coupled receptor agonists, gastrointestinal peptide agonists other than GLP-1, apical sodium-dependent bile acid transporter (ASBT) inhibitors, SGLT1 and dual SGLT1/SGLT2 inhibitors, and 11beta- HSD1 inhibitors.
Keywords: Antidiabetic drugs, new characteristics, new drug development, new insulins, new mechanisms of action, personalized medicine, type 2 diabetes.
Current Diabetes Reviews
Title:Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development
Volume: 11 Issue: 1
Author(s): Friedrich Mittermayer, Erica Caveney, Claudia De Oliveira, Loukas Gourgiotis, Mala Puri, Li-Jung Tai and J. Rick Turner
Affiliation:
Keywords: Antidiabetic drugs, new characteristics, new drug development, new insulins, new mechanisms of action, personalized medicine, type 2 diabetes.
Abstract: The global burden of type 2 diabetes is increasing worldwide, and successful treatment of this disease needs constant provision of new drugs. Twelve classes of antidiabetic drugs are currently available, and many new drugs are under clinical development. These include compounds with known mechanisms of action but unique properties, such as once-weekly DPP4 inhibitors or oral insulin. They also include drugs with new mechanisms of action, the focus of this review. Most of these compounds are in Phase 1 and 2, with only a small number having made it to Phase 3 at this time. The new drug classes described include PPAR agonists/modulators, glucokinase activators, glucagon receptor antagonists, anti-inflammatory compounds, G-protein coupled receptor agonists, gastrointestinal peptide agonists other than GLP-1, apical sodium-dependent bile acid transporter (ASBT) inhibitors, SGLT1 and dual SGLT1/SGLT2 inhibitors, and 11beta- HSD1 inhibitors.
Export Options
About this article
Cite this article as:
Mittermayer Friedrich, Caveney Erica, De Oliveira Claudia, Gourgiotis Loukas, Puri Mala, Tai Li-Jung and Turner J. Rick, Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development, Current Diabetes Reviews 2015; 11 (1) . https://dx.doi.org/10.2174/1573399810666141224121927
DOI https://dx.doi.org/10.2174/1573399810666141224121927 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Improved Synthesis of m-Hydroxymexiletine, a Potent Mexiletine Metabolite
Drug Metabolism Letters Cytotoxic and Allergenic Potential of Bioactive Proteins and Peptides
Current Pharmaceutical Design An Inducible Expression System for Recombinant Sca Proteins with an Autotransporter Domain from <i>Orientia Tsutsugamushi in Escherichia coli</i>
Protein & Peptide Letters Human Ascariasis: An Updated Review
Recent Patents on Inflammation & Allergy Drug Discovery Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry Current Key Points in Management for Severe Community-Acquired Pneumonia
Current Respiratory Medicine Reviews Contemporary Pharmacologic Management of Heart Failure with Reduced Ejection Fraction: A Review
Current Cardiology Reviews Calcium Homeostasis and Kinetics in Heart Failure
Medicinal Chemistry Noradrenaline in Parkinsons Disease: From Disease Progression to Current Therapeutics
Current Medicinal Chemistry Glaucoma and Aging
Current Aging Science Long-Term Use of Short- and Long-Acting Nitrates in Stable Angina Pectoris
Current Clinical Pharmacology Anti-VEGF Strategies – from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer
Current Pharmaceutical Design Reduction of Sympathetic Hyperactivity by Agents that Inhibit the Renin Angiotensin Aldosterone System
Current Hypertension Reviews Herpes Simplex Virus-Induced Ocular Diseases: Detrimental Interaction Between Virus and Host
Current Immunology Reviews (Discontinued) Biochemical Markers in the Prediction of Contrast-induced Acute Kidney Injury
Current Medicinal Chemistry Identification of L-Amino Acid Oxidase (Mb-LAAO) with Antibacterial Activity in the Venom of Montivipera bornmuelleri, a Viper from Lebanon
Infectious Disorders - Drug Targets Thromboxane Synthase Inhibitors and Thromboxane A2 Receptor Antagonists: A Quantitative Structure Activity Relationships (QSARs) Analysis
Current Medicinal Chemistry Allergy to Miscellaneous Household Arthropods
Protein & Peptide Letters Role of Catechol-O-Methyltransferase (COMT)-Dependent Processes in Parkinson’s Disease and L-DOPA Treatment
CNS & Neurological Disorders - Drug Targets Hypotensive Effects of the Triterpene Oleanolic Acid for Cardiovascular Prevention
Current Molecular Pharmacology